The aggregate knowledge gained by exploring BACE1 deletion mutants and characterizing BACE1 substrates has downstream implications for identifying AD medication treatments and anticipating the adverse effects of BACE1 inhibitors [97]. The gene discussed is BACE1; the disease is Alzheimer disease.